(Total Views: 659)
Posted On: 09/22/2022 1:32:57 PM
Post# of 148878
I can't find that this has been posted to this board before -
https://www.science.org/content/article/scien...e-analysts
https://www.science.org/content/article/compe...-vignettes
These articles show that we are very lucky to have Cyrus Arman on our team, eventually to be our CEO.
It is obvious that it was Arman's choice to join us. He must see Cytodyn and Leronlimab as the vehicles to making his mark in medicine and even history. He's not wrong!
I have no doubt that he will become highly known and respected around the world should he get Leronlimab to market and applied to the many indications it is capable of treating. This is a powerful match - Arman, Cytodyn and Leronlimab!
With Tanya's help keeping Cytodyn on the regulatory straight and narrow and Migliarese doing a great financial job as far as I can tell, I can't help thinking that Cytodyn's eventual success is assured! We have as good a team as a small biotech can hope for!
I hope that, with this team, all the problems Cytodyn has are "solveable", as Scott Kelly has said. It is just a real shame that the Pandemic, an opportunity as an accelerator for getting to fast approval, was squandered. Now, approval will probably take a good deal longer unless valid data from past trials can be retrieved.
From one of the articles -
"Ph.D.s have a range of analytical skills, which (competitive-intelligence) analysts need to squeeze valuable information out of a broad range of sources. Ph.D.s are also able to learn quickly; CI analysts often have little time to familiarize themselves with a new field. Conveying findings to non-experts, such as a company's senior management team, is also part of a CI job..." But Arman IS senior management! Hot Dog!
Arman will quickly understand the whole of Cytodyn and Leronlimab and it's predicaments and, I am confident, will chart a path to terrific success. In my opinion, a real Phoenix story!
GLTAL!
https://www.science.org/content/article/scien...e-analysts
https://www.science.org/content/article/compe...-vignettes
These articles show that we are very lucky to have Cyrus Arman on our team, eventually to be our CEO.
It is obvious that it was Arman's choice to join us. He must see Cytodyn and Leronlimab as the vehicles to making his mark in medicine and even history. He's not wrong!
I have no doubt that he will become highly known and respected around the world should he get Leronlimab to market and applied to the many indications it is capable of treating. This is a powerful match - Arman, Cytodyn and Leronlimab!
With Tanya's help keeping Cytodyn on the regulatory straight and narrow and Migliarese doing a great financial job as far as I can tell, I can't help thinking that Cytodyn's eventual success is assured! We have as good a team as a small biotech can hope for!
I hope that, with this team, all the problems Cytodyn has are "solveable", as Scott Kelly has said. It is just a real shame that the Pandemic, an opportunity as an accelerator for getting to fast approval, was squandered. Now, approval will probably take a good deal longer unless valid data from past trials can be retrieved.
From one of the articles -
"Ph.D.s have a range of analytical skills, which (competitive-intelligence) analysts need to squeeze valuable information out of a broad range of sources. Ph.D.s are also able to learn quickly; CI analysts often have little time to familiarize themselves with a new field. Conveying findings to non-experts, such as a company's senior management team, is also part of a CI job..." But Arman IS senior management! Hot Dog!
Arman will quickly understand the whole of Cytodyn and Leronlimab and it's predicaments and, I am confident, will chart a path to terrific success. In my opinion, a real Phoenix story!
GLTAL!
(11)
(0)Scroll down for more posts ▼
